How many drugs treat Myocardial infarction?

Drug Landscape tracks 10 marketed treatments for Myocardial infarction (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/myocardial-infarction.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Myocardial infarction — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Myocardial infarction (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Myocardial infarction, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Tryvio	APROCITENTAN	Idorsia	Endothelin Receptor Antagonist [EPC]		2025-01-01
Lovenox (Preservative Free)	ENOXAPARIN SODIUM	Sanofi	Low Molecular Weight Heparin	Antithrombin-III	1993-01-01
Zestril	lisinopril	Generic (originally Merck/AstraZeneca)	Thiazide Diuretic [EPC]	Angiotensin-converting enzyme, Angiotensin-converting enzyme	1987-12-29
Tenoretic 100	ATENOLOL	Twi Pharms	beta-Adrenergic Blocker [EPC]	Adenosine receptor A3	1981-01-01
Lopressor	metoprolol	Generic (originally Ciba-Geigy/Novartis)	Beta-1 selective blocker	Beta-1 adrenergic receptor, Beta-2 adrenergic receptor, 5-hydroxytryptamine receptor 1A	1978-08-07
Norgesic	acetylsalicylic acid	Endo	centrally acting muscle relaxant with anticholinergic properties	reticular formation (brain stem)	1950-01-01
Dicuman	dicoumarol	AbbVie	dicoumarol	NAD(P)H dehydrogenase [quinone] 1	1944-01-01
Lisinopril/HCTZ	HCTZ	Direct_Rx	Thiazide Diuretic [EPC]
Lovenox	Lovenox	University of Monastir		Antithrombin-III
Enoxaparin	Enoxaparin	Dana-Farber Cancer Institute		Antithrombin-III

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

AbbVie · 1 drug in Myocardial infarction
Dana-Farber Cancer Institute · 1 drug in Myocardial infarction
Direct_Rx · 1 drug in Myocardial infarction
Endo · 1 drug in Myocardial infarction
Generic (originally Ciba-Geigy/Novartis) · 1 drug in Myocardial infarction
Generic (originally Merck/AstraZeneca) · 1 drug in Myocardial infarction
Idorsia · 1 drug in Myocardial infarction
Sanofi · 1 drug in Myocardial infarction
Twi Pharms · 1 drug in Myocardial infarction
University of Monastir · 1 drug in Myocardial infarction

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Myocardial infarction:

Cite this brief

Drug Landscape (2026). Myocardial infarction — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/myocardial-infarction. Accessed 2026-06-10.

Myocardial infarction full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing